# Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC

> **NCT04699721** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Xiangya Hospital of Central South University** · enrollment: 60 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Stage II
- Non-small Cell Lung Cancer Stage ⅢA
- Non-small Cell Lung Cancer Stage IIIB

## Interventions

- **DRUG:** nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5

## Key facts

- **NCT ID:** NCT04699721
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-01
- **Primary completion:** 2027-09
- **Final completion:** 2027-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04699721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04699721, "Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04699721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*